Invention Grant
- Patent Title: Soluble IL-17RCx4 and fusion proteins thereof
- Patent Title (中): 可溶性IL-17RCx4及其融合蛋白
-
Application No.: US12580112Application Date: 2009-10-15
-
Publication No.: US08093355B2Publication Date: 2012-01-10
- Inventor: Rolf E. Kuestner , Zeren Gao , Steven D. Levin , Mark W. Rixon
- Applicant: Rolf E. Kuestner , Zeren Gao , Steven D. Levin , Mark W. Rixon
- Applicant Address: US WA Seattle
- Assignee: ZymoGenetics, Inc.
- Current Assignee: ZymoGenetics, Inc.
- Current Assignee Address: US WA Seattle
- Agency: Nelson Mullins Riley & Scarborough LLP
- Agent Jane E. Remillard, Esq.; Jill Gorny Sloper, Esq.
- Main IPC: C07K1/00
- IPC: C07K1/00 ; C07K14/00 ; C07K17/00
Abstract:
The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17F, IL-17A, or both IL-17A and IL-17F polypeptide molecules. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. IL-17RC is a common receptor for IL-17A and IL-17F. The present invention includes methods of using a soluble IL-17RC receptor, IL-17RCx4 for treating inflammation.
Public/Granted literature
- US20100113748A1 SOLUBLE IL-17RCX4 AND METHODS OF USING IN INFLAMMATION Public/Granted day:2010-05-06
Information query
